Trial Profile
A Phase II, Randomised, Double-blind, Placebo-controlled and Parallel Group Study to Evaluate the Safety and Efficacy of Four Weeks Treatment of 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d. BIBW 2948 BS (Inhalation Powder, Hard Capsule for HandiHaler) in Patients With COPD Associated With Chronic Bronchitis.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs BIBW 2948 BS (Primary)
- Indications Chronic bronchitis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 01 Apr 2022 This trial has been completed in France, according to EudraCT record.
- 24 May 2012 Official title amended as reported by European Clinical Trials Database.
- 24 Sep 2008 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.